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  EVIDENCE-BASED ANSWER 
In pregnant women with preexisting type 1 diabetes mellitus, maintaining near-normal blood glucose levels 
decreases the rate of major congenital anomalies (defined as those causing death or a serious handicap 
necessitating surgical correction or medical treatment). Prolonged preconception control of blood sugar to near 
normal levels reduces the rate of major congenital anomalies close to those seen in women without diabetes 
(strength of recommendation [SOR]: A, based on prospective cohort studies and randomized controlled trial 
[RCT]). 
Intensive management reduces the risk of congenital anomalies more than conventional therapy, and lowers 
the risk of neonatal hypoglycemia (SOR: B, based on RCT). Very tight control does not reduce clinically 
significant neonatal morbidity but does increase the risk of maternal hypoglycemia (SOR: B, based on a 
systematic review). Evidence is insufficient about whether or not these statements hold true for women with 
type 2 diabetes. 
In women with impaired glucose tolerance, dietary control reduces neonatal hypoglycemia. To date, studies 
have not found statistically significant reductions in admission rates to the special care nursery or birth weights 
above the 90th percentile (SOR: B, systematic review). Evidence is insufficient to suggest improved outcomes 
with therapy in women with gestational diabetes. Standard recommendations typically recommend tight control 
in this population as well. 
  EVIDENCE SUMMARY 
Two studies show that in type 1 diabetes mellitus, elevated blood glucose levels in early pregnancy 
(HbA1c=6%–8%) are associated with a threefold increase in fetal malformations.1,2 Maintaining preconception 
and early pregnancy blood glucose levels in the normal range can reduce this risk. A meta-analysis comparing 
16 studies of women with pregestational diabetes—13 of which included only women with type 1 diabetes—
found that women receiving preconception care had lower early first trimester HbA1c levels than those who did 
not (7.9% vs 9.6%) and delivered fewer infants with major congenital anomalies (relative risk [RR]=0.36; 95% 
confidence interval [CI], 0.22–0.59).2 One limitation of this study was that preconception care was not 
consistently defined among the included studies. 
A 10-year RCT evaluated the outcomes of 270 pregnancies in women who had received either intensive (SQ 
infusion or multiple daily injections) or conventional insulin regimens prior to pregnancy. Women were advised 
to use intensive therapy when they were trying to conceive, and all were changed to intensive therapy if 
pregnancy was confirmed. Women in the intensive therapy group had normal HbA1c levels for an average of 40 
months before conception. Women receiving intensive therapy had lower mean HbA1c levels at conception (7.4 
± 1.3 SD vs 8.1 ± 1.7 SD) and fewer major congenital anomalies (0.7% vs 5.9%; number needed to treat=19) 
than did women in the conventional group. When infants with genetic malformations were excluded from the 
analysis, rates of congenital malformations were similar in women switched to intensive therapy either before 
or after conception (3.8% vs 3.6%). No differences were seen between neonatal mortality, spontaneous 
abortion rates, birth weights, Apgar scores, and hypocalcemia or hypoglycemia rates.3 
When tight and very tight control of glucose in pregnant women with pregestational diabetes were compared in 
a Cochrane systematic review, rates of maternal hypoglycemia in the very tightly controlled group were higher 
(odds ratio [OR]=25.96; 95% CI, 4.91–137.26).5 An RCT of 118 women with pregestational diabetes compared 
4-times-daily vs twice-daily doses of insulin. Infants born to women receiving 4-times-daily insulin had 
significantly lower rates of neonatal hypoglycemia (RR=0.17; 95% CI, 0.04–0.74). While the trend was toward 
improved neonatal metabolic effects in the trials, the clinical significance of these findings is not clear. 
Whether or not treatment of gestational diabetes improves outcomes is uncertain. A Cochrane systematic 
review evaluating a small number of trials, with variable quality and inconsistent outcome measures, compared 
dietary management to routine care in gestational diabetics. While fewer infants with birth weights >4000 g 
were delivered in the diet therapy group (OR=0.78; 95% CI, 0.45–1.35), the results were not statistically 
significant. No other important clinical differences were found.6 
Another Cochrane systematic review evaluated the effects of dietary treatment of women with impaired 
glucose tolerance and gestational diabetes. Three trials with a total of 223 women with impaired glucose 
tolerance found a significant reduction in the rate of neonatal hypoglycemia (RR=0.25; 95% CI, 0.07–0.86). 
There was no significant change in the rates of cesarean section (RR=0.86; 95% CI, 0.51–1.45), admission to 
the special care nursery (RR=0.49; 95% CI, 0.19–1.24), or birth weights greater than the 90th percentile 
(RR=0.55; 95% CI, 0.19–1.61). Inadequate power may well account for the failure to reach significance in 
these outcomes.7 
  RECOMMENDATIONS FROM OTHERS 
The American College of Obstetrics and Gynecology (ACOG) recommends that women with pregestational 
diabetes maintain fasting plasma glucose levels between 60–90 mg/dL and 2-hour postprandial levels <120 
mg/dL.8 For women with gestational diabetes who are not controlled within these targets on dietary therapy 
alone, ACOG recommends the additional of insulin therapy.9 
The American Diabetes Association recommends that women with pregestational diabetes maintain capillary 
plasma glucose levels of 80–110 mg/dL before and <155 mg/dL 2 hours after meals before pregnancy and 
while trying to conceive.10 The ADA does not list target glucose levels for women with pregestational diabetes 
once they become pregnant. The ADA recommends the use of diet and insulin therapy to maintain preprandial 
plasma glucose levels of <105 mg/dL and 2-hour postprandial levels below <130 mg/dL in gestational 
diabetes.11 
CLINICAL COMMENTARY 
Glucose control makes a difference for pregnancy 
outcomes in type I diabetes 
 
Linda  French,  MD 
Michigan State University,East Lansing 
It is well accepted that glucose control makes a difference for pregnancy outcomes in 
women with type 1 diabetes. Since similar studies have not been done in women with 
preexisting type 2 diabetes, we have to assume that the risk is also high for them. 
Preconception counseling about glucose control is so important for women with diabetes. 
Fortunately, because they generally have routine visits for their chronic care, we have an 
opportunity to initiate discussion of glucose control in relationship to pregnancy planning. 
Routine diabetes care visits also give us the opportunity to discuss other important 
preconception topics. 
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D R U G  B R A N D  N A M E S  
Allopurinol • Lopurin, Zyloprim 
Amitriptyline • Elavil, Endep 
Benzbromarone • Urinorm 
Botulinim toxin A • Botox 
Clindamycin • Cleocin 
Fluoxetine • Prozac 
Fluticasone • Flovent 
Gabapentin • Neurontin 
Metronidazole (intravaginal) • MetroGel 
Probenecid • Benemid, Probalan 
Sumatriptan • Imitrex 
Tizanidine • Zanaflex 
Triamcinolone • Azmacort 
Valproate • Depacon 
 
